Literature DB >> 3939104

Plasma gastrin and gastric acid responses to insulin hypoglycemia in Chagas' disease.

L E Troncon, R B Oliveira, U G Meneghelli, R O Dantas, R A Godoy.   

Abstract

Plasma gastrin and gastric acid responses to intravenous injection of insulin (0.2 IU/kg) were measured in 8 patients with Chagas' disease, which is known to be associated with extensive reduction of the intramural neurons of the digestive tract, and in 6 control subjects. All subjects developed hunger, sweating and tachycardia, and exhibited less than 50 mg/dl venous blood glucose. Plasma gastrin responses in Chagas' disease patients (median: 3.60 nmol L-1 min-1; range: 1:12 to 10.60 nmol L-1 min-1) were significantly higher than for control subjects (median: 0.52 nmol L-1 min-1; range: 0.25 to 1.09 nmol L-1 min-1). Gastric acid output was significantly lower in Chagas' disease patients (median: 3.5 mmol/h; range: 2.1 to 13.6 mmol/h) than in controls (median: 30.3 mmol/h; range: 7.3 to 38.2 mmol/h). These data show that chagasic patients have abnormally high gastrin release and low gastric acid secretion in response to insulin, and thus indicate that loss of intrinsic innervation of the stomach does not abolish the gastrin response to insulin hypoglycemia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3939104

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  2 in total

1.  Preoperative gastric acid secretion and the risk to develop Barrett's esophagus after esophagectomy for chagasic achalasia.

Authors:  Julio Rafael Mariano da Rocha; Ivan Cecconello; Ulysses Ribeiro; Elisa R Baba; Adriana Vaz Safatle-Ribeiro; Kiyoshi Iriya; Rubens A A Sallum; Paulo Sakai; Sérgio Szachnowicz
Journal:  J Gastrointest Surg       Date:  2009-09-09       Impact factor: 3.452

Review 2.  The chronic gastrointestinal manifestations of Chagas disease.

Authors:  Nilce Mitiko Matsuda; Steven M Miller; Paulo R Barbosa Evora
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.